Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Inclusion Criteria:

• Age > 18 yo.
• Primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in the largest vessel diameter and 6 mm or less in the apical height.
• Location of the tumor posterior to the equator.
• Documented growth by A/B scan.
• Risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at the optic disc)
• Ability to provide inform consent.
• Comply with the study assessment for the cooperation of the study.

Exclusion Criteria:

• Pregnancy or lactation.
• Premenopausal women not using adequate contraception; surgical sterilization or use of oral contraception, barrier contraception with either a condom or diaphragm or in conjunction with spermicidal gel, an IUD or contraceptive hormon implant or patch.
• Current infection or inflammation in either eye.
• Extension of tumor into the orbit.
• Retinal spread or metastatic disease.
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
• Any known allergy to any of the components to be used in the study.
• Participation in another simultaneous medical investigation or trial.